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Objective: Approximately 10% of infrainguinal bypass surgeries are complicated by early conduit failure. The cause is
unclear in most cases. A prospective study was conducted to monitor the development and function of platelet factor 4
(PF4)/heparin antibodies after infrainguinal bypass procedures and to evaluate their clinical significance in early graft
occlusion.
Methods: Blood samples were obtained before surgery and at the 7-, 14-, and 28-day postsurgical evaluation. Relevant
demographic and laboratory data were collected, and plasma samples were assayed for the presence and function of
PF4/heparin-antibody by enzyme-linked immunosorbent assay (ELISA) and a two-point platelet aggregation assay. All
tests were performed in duplicate or triplicate.
Results:Of the 79 patients who were enrolled, 67 reported previous heparin exposure. Six patients (7.6%) tested positive
for the presence of PF4/heparin antibodies before surgery with ELISA, and four of these (67%) also had a positive result
on the aggregation assay. During the 28-day follow-up, 22 subjects (32%) converted to positive according to the ELISA
results; and five (22.7%) of these also tested positive for platelet-activating antibodies. No participants presented with
thrombocytopenia or a >50% decrease in platelet count during the study period. Early graft occlusion was detected in
three patients, all with negative ELISA and functional assay results throughout the study.
Conclusion: Patients undergoing vascular surgery frequently develop PF4/heparin antibodies, with platelet-activating
antibodies detected in up to 11% of these individuals. However, thrombocytopenia and vascular graft thrombosis both
appear to be an uncommon consequence. (J Vasc Surg 2008;48:377-81.)Approximately 10 million individuals have symptom-
atic peripheral artery disease in the United States, and
almost 100,000 reconstructive procedures performed an-
nually.1 Owing to the refinements in conduit selection and
operative techniques, aortoiliac and femoropopliteal bypass
surgeries can provide effective revascularization and a favor-
able immediate operative result for most patients, thus
reducing the incidence and complications of peripheral
ischemia.2
However, subsequent graft closure is not uncommon
and poses a significant clinical problem. Early graft failure is
observed in up to 10% of patients owing to the acute
thrombotic occlusion of the conduit.3 The incidence of late
graft stenosis is reported to reach 30% due to intimal
hyperplasia at the proximal anastomosis or near the valve
leaflets.4 Advanced atherosclerosis of the contiguous arter-
ies predisposes these vessels to clamp injury during the
bypass procedure, further increasing the risk of late graft
failure.
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doi:10.1016/j.jvs.2008.03.028The underlying cause of early conduit occlusion is less
clearly understood, with multiple possible pathologic
mechanisms implicated. These can involve anatomic or
structural defects of the bypass graft promoting early
thrombosis, postsurgical conditions leading to a prothrom-
botic state, inflow disease, or poor runoff.3,5 We recently
observed recurrent, early conduit thrombosis in two pa-
tients after lower extremity bypass procedures who were
subsequently diagnosed with heparin-induced thrombocy-
topenia (HIT). Thus, we conducted this prospective study
to evaluate the development of platelet factor 4 (PF4)/
heparin antibodies after infrainguinal bypass surgery and to
explore the pathophysiologic significance of HIT in early
graft occlusion.
METHODS
Consecutive adult patients undergoing infrainguinal
bypass surgery for atherosclerotic occlusive vascular disease
at the Los Angeles County-University of Southern Califor-
nia (USC) Medical Center or USC University Hospital
were eligible for the study. All relevant demographic and
clinical data were collected, and serial measurements of
enzyme-linked immunosorbent assay (ELISA) were per-
formed with platelet aggregometry to test for the titer and
activity of PF4/heparin antibodies. No routine preopera-
tive screening was used with ELISA or platelet aggregom-
etry. Samples in the present study were batch tested so that
assay results were often not available until days to weeks
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HIT, who immediately underwent laboratory testing.
Clinical HIT was defined by the development of
thrombocytopenia (platelet count 100,000/L) or a
50% drop in platelet count, with or without thrombosis.
Enrolled patients received only a single dose of unfraction-
ated heparin intraoperatively (average dose, 6088  1246
U). No patients were re-exposed to heparin in the postop-
erative period. All participants provided informed consent,
and the study was approved by the Human Subjects Com-
mittee of the Keck School of Medicine, USC.
Exclusion criteria included failure to sign informed
consent, uncertain patient follow-up, individuals with
known allergy to heparin, and any history of HIT. A 30-mL
blood sample was obtained by sterile antecubital venipunc-
ture into citrate (3.2%) from eligible subjects preoperatively
on the day of surgery (before the administration of heparin)
and at the 7-, 14-, and 28-day postsurgical evaluation.
Plasma was isolated by centrifugation (2500g, 10 minutes)
and stored at 80°C until assayed.
All samples were tested for the presence of PF4/hepa-
rin antibodies using a commercially available ELISA kit
(Asserachrom HPIA, Diagnostica Stago, Parsippany, NJ).
Absorbance was measured at 492 nm; the cutoff value for a
positive test result was specific for each assay and was
provided by the manufacturer. For the purposes of the
study, positive ELISA results were analyzed in quartiles,
with quartile 4 representing subjects with the highest anti-
body titer. Tests were performed in duplicate or triplicate.
All ELISA-positive and selected negative patient sam-
ples were further tested for their ability to promote platelet
activation using a two-point aggregation assay. Initially, 12
healthy, drug-free volunteers were prescreened for platelet
reactivity to PF4/heparin antibodies using plasma samples
known to be positive for HIT, and four sensitive donors
were identified. Approximately 40 mL of blood was col-
lected from these volunteers by sterile antecubital veni-
puncture into anticoagulant citrate dextrose solution. Sam-
ples were centrifuged immediately at 150g for 10 minutes
to separate platelet-rich plasma (PRP). Meanwhile, a batch
of patient plasmas was defrosted in a 37°C waterbath,
followed by heat inactivation (56°C for 45 minutes) and
centrifugation (2500g, 10 minutes). Supernatants were
removed and used as platelet-poor plasma (PPP) for the
functional assay.
Aliquots of 145 L of PRP and 145 L of test PPP
were combined and preincubated at 37°C for 3 minutes in
plastic corvettes. Upon testing, 10 L of unfractionated
heparin (American Pharmaceuticals Partners, Inc, Scham-
burg, Ill) was added to the samples, yielding the final
concentrations of 0.5 U/mL and 100 U/mL. An equal
volume of physiologic saline was mixed to the control
corvettes (negative control).
Platelet function was monitored and aggregation
curves were recorded at 37°C for 15 minutes with a Carat
TX-4 platelet aggregometer (Carat Ltd, Budapest, Hun-
gary), using the turbidimetric method described by Born
and Cross.6 Maximal aggregation was expressed as a per-centage of 100% light transmission, calibrated for each
specimen. The functional assay was considered positive if
the change in optical density exceeded 20% upon the
addition of 0.5 U/mL heparin, with no aggregation in the
presence of 100 U/mL of heparin and in the control
sample.
Platelet response was deemed nonspecific and thus
negative if positive assay results were obtained with both
heparin concentrations tested. Negative samples were re-
tested with adenosine diphosphate (final concentration,
5M), collagen (2 g/mL), and epinephrine (10M) to
ensure the viability of donor platelets. All functional assays
were performed in duplicate and were repeated on at least
two sensitive donors to reduce false-positive and false-
negative results. To be deemed a positive assay, positive
aggregation assays had to be obtained from both sensitive
platelet donors.
RESULTS
The study enrolled 79 subjects (42 men, 37 women;
mean age, 67  12 years) undergoing infrainguinal bypass
surgery. An autogenous conduit was used in 68 patients, a
prosthetic graft in nine, and a biograft in two. No partici-
pants had significant liver function impairment or any fam-
ily history for coagulation or bleeding disorders. Seventy
patients (89%) reported previous heparin exposure. De-
tailed characteristics of the study population are summa-
rized in Table I.
Of the 79 enrolled subjects, 28 (35.4%) had at least one
ELISA-positive blood sample, with nine (11%) positive in
the aggregation assay. Six patients (7.6%) tested positive for
PF4/heparin antibody by ELISA before the surgery, with
four of the six specimens (67%) also positive in the func-
tional assay. Antibody titers increased after surgery in four
of the six patients. Seventy-three subjects (92%) provided
all four blood samples described in the protocol, only the
presurgical specimen was collected from six patients (8%).
Of the 68 follow-up patients, 22 (32.3%) with a negative
presurgical test result produced antibodies to the PF4/
heparin complex during the postsurgical evaluations. Two
of the nine patients with no previous heparin exposure
seroconverted in the postoperative period. All participants
developed a positive ELISA result by day 14 (Table II).
Five subjects (22.7%) tested positive in the functional plate-
let assay.
No patient in our series showed any laboratory assays
results, clinical signs, or symptoms suggestive for HIT.
Also, none of the ELISA-positive patients developed early
graft closure, despite the presence of platelet-activating
antibodies in nine subjects (Table II). In contrast, early
conduit occlusion was detected in three participants, and all
of them tested negative with ELISA and the functional
assay.
DISCUSSION
HIT is of special interest for vascular surgeons inas-
much as heparin is the predominant anticoagulant used to
prevent or treat perioperative thrombotic complications. It
ay; SD
elet co
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induced autoimmune disorder characterized by antibody
formation against the complex of heparin and PF4.7,8
Antibodies of the immunoglobulin G subclass bind to
platelets through the FcRIIa receptor and induce their
activation, microparticle release, and thrombin generation,
thus promoting a hypercoagulable state.9-12 The develop-
ment of a new thrombotic complication, a reduction in
platelet count50%, or unexplained heparin resistance are
possible clinical indicators for HIT, typically appearing 5 to
10 days after heparin exposure.13,14 Once HIT is sus-
pected, rapid laboratory confirmation is required; the most
commonly used tests include ELISA to detect the titer and
two functional assays (ie, serotonin release assay, two-point
platelet aggregation test) to explore the functionality of
PF4/heparin antibodies.15,16
The incidence of HIT is dependent on the patient
population studied and is reported to be 0.3% to 2.7%; HIT
complications, such as HIT thrombosis (HITT), are de-
tected in approximately 50% of these subjects.17,18 Venous
or arterial thrombi might develop days or even weeks after
Table 1. Patient characteristics
Variables All patie
Subjects, No. 79
Age, mean (SD) years 67 (12
Males/females 0.54
Average heparin dose, mean (SD) U 6088 (12
Previous heparin exposure, % 84.8
Previous warfarin exposure, % 20.3
Hypertension, % 87.3
Diabetes mellitus, % 73.4
History of thrombocytopenia, % 5.1
History of DVT, % 10.1
Positive functional assay, % 11.4
DVT, Deep venous thrombosis; ELISA, enzyme-linked immunosorbent ass
Table II. Follow-up laboratory data
Pre-op (n  79) Day 7 (
ELISA ELISA ELISA
Patients, No. (%) 6 (7.6) 73 (92.4) 14 (20.6)
New ELISA
patients, No.
6 . . . 10
Positive functional
assay (n)
4 0 3
Platelet count,
mean (SD)
	109/L
251.0
(124.5)
276.9
(87.05)
340.3
(150.0)
Patients with
HIT, No.a
None None None
Early graft
occlusion, No.
0 0 0
ELISA, Enzyme-linked immunosorbent assay; HIT, heparin induced throm
aClinical HIT was defined as the development of thrombocytopenia (plat
thrombosis.heparin exposure, suggesting that HIT might be implicatedin early graft occlusion after lower extremity bypass proce-
dures.19,20 Despite the potentially serious clinical complica-
tions of HIT, only a limited number of prospective studies
have focusedonpatients undergoing vascular surgery. Jackson
et al21 used ELISA to evaluate the development of PF4/
heparin antibodies in 54 patients. They found that only one
subject converted to positive after surgery, and one throm-
botic complication was recorded that was independent of the
patient’s ELISA status. No functional platelet tests were per-
formed in these series, however.
Calaitges et al22 conducted a prospective study to in-
vestigate the incidence and clinical significance of heparin-
associated antiplatelet antibodies in 106 subjects undergo-
ing major vascular reconstruction. A two-point platelet
aggregation assay was performed before surgery and at
least 4 days after the intervention; 22 patients (21%) had
at least one positive test result. Although statistically not
significant (P .21), the authors found that the presence of
functionally active heparin-associated antiplatelet antibod-
ies is associated with a 2.6-fold increased risk for perioper-
ative thrombotic complications, with thrombocytopenia
ELISA ELISA
28 51
65 (9) 69 (11)
0.64 0.45
6026 (1241) 6167 (1291)
85.7 84.3
28.6 15.7
89.3 86.3
71.4 74.5
3.6 5.9
10.7 9.8
32.1 0
, standard deviation.
8) Day 14 (n  68) Day 28 (n  68)
ISA ELISA ELISA ELISA ELISA
(79.4) 23 (33.8) 45 (66.2) 17 (25.0) 51 (75.0)
. . . 12 . . . 0 . . .
0 1 0 1 0
9.5
76.2)
329.0
(141.0)
410.0
(94.4)
287.2
(124.4)
286.7
(69.4)
one None None None None
3 0 0 0 0
openia.
unt 100,000/L) or a 50% drop in platelet count, with or withoutnts
)
46)n  6
EL
54
33
(
N
bocytbeing an unreliable clinical marker.
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patients undergoing vascular surgery. All participants re-
ceived intravenous unfractionated heparin for 5 days
preoperatively. The therapy was continued for 7 days after
surgery and was followed by the administration of subcu-
taneous low-molecular-weight heparin for 9 days.23 After
ceasing the heparin treatment, 34% of patients were positive
in the PF4/heparin antibody ELISA and 14% in the func-
tional test, with no association between the assay results
and the clinical manifestations of HIT.
The purpose of this prospective study was to determine
the incidence of PF4/heparin antibodies by ELISA and test
their functionality using a two-point platelet aggregation
assay in patients undergoing infrainguinal reconstructive
surgery. Assay results and short-term surgical outcome of
incidence of early graft thrombosis 28 days postopera-
tively were also compared to evaluate the clinical signifi-
cance of PF4/heparin antibodies.
Pre-existing PF4/heparin antibodies were detected in
six subjects (7.6%) before the bypass procedure, despite the
extensive history of heparin exposure in our study popula-
tion. When present, however, these antibodies were found
to be functionally active in the platelet aggregation assay in
four patients (67%). After the single unfractionated heparin
exposure used in the present study, ELISA-detected PF4/
heparin antibodies developed in 22 patients (32%). The
incidence of seroconversion increased from 14.4% on post-
operative day 7 to 17.6% on day 14, with no new ELISA-
positive patients detected on day 28. Of the nine patients
with no previous heparin exposure, two were identified
to have PF4/heparin antibodies present by postoperative
day 14.
Five of the 22 subjects (23%) tested positive with
platelet aggregometry; the antibody titer of these patients
were all in the highest quartile, as determined by ELISA.
However, not all subjects in quartile 4 tested positive in the
functional assay; thus, we were unable to establish a close
correlation between the results of the two laboratory tests.
Despite the frequent appearance of PF4/heparin anti-
bodies after infrainguinal bypass surgery, none of our pa-
tients developed thrombocytopenia or any other clinical
symptoms characteristic for HIT. This observation most
likely is due to the single intraoperative heparin exposure
and the absence at our institution of routine postoperative
heparin infusions after lower extremity revascularization.
However, the documentation of nine patients having PF4/
heparin antibodies with positive platelet aggregation stud-
ies in the postoperative period suggests that prolonged
heparin infusions may put patients at risk for HIT and
HITT and, consequently, should be used sparingly. Also,
the titer and biologic activity of PF4/heparin antibodies
showed no correlation with the incidence of early conduit
failure in our study population. Three patients presented
with early graft thrombosis on postoperative day 7; how-
ever, samples from all these subjects tested negative with
ELISA and did not promote platelet aggregation in the
functional assay.CONCLUSION
Patients undergoing vascular surgery frequently de-
velop PF4/heparin antibodies, with platelet-activating an-
tibodies detected in up to 11% of the population. However,
both thrombocytopenia and early conduit thrombosis ap-
pear to be an uncommon consequence.
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